This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 90/4/465    most recent hh0402.105372v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by McLean, P. G. Articles by Ahluwalia, A. Search for Related Content PubMed PubMed Citation Articles by McLean, P. G. Articles by Ahluwalia, A. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CAPSAICIN POTASSIUM Related Collections Cardiovascular Pharmacology Ischemic biology - basic studies Acute myocardial infarction Receptor pharmacology Endothelium/vascular type/nitric oxide

(Circulation Research. 2002;90:465.)
© 2002 American Heart Association, Inc.

Integrative Physiology

Protease-Activated Receptor-2 Activation Causes EDHF-Like Coronary Vasodilation

Selective Preservation in Ischemia/Reperfusion Injury: Involvement of Lipoxygenase Products, VR1 Receptors, and C-Fibers

Peter G. McLean, Daniel Aston, David Sarkar, Amrita Ahluwalia

From the Centre for Clinical Pharmacology, Department of Medicine (P.G.M., D.A., D.S.), University College London; and the Centre for Clinical Pharmacology, William Harvey Research Institute (P.G.M., A.A.), St Bartholemew’s Medical College, London, UK.

Correspondence to Dr P.G. McLean, Centre for Clinical Pharmacology, William Harvey Research Institute, London EC1M 6BQ, UK. E-mail a.ahluwalia{at}qmul.ac.uk

Activation of protease-activated receptor (PAR)-2 has been proposed to be protective in myocardial ischemia/reperfusion (I/R) injury, an effect possibly related to an action on the coronary vasculature. Therefore, we investigated the effects of PAR2 activation on coronary tone in isolated perfused rat hearts and elucidated the mechanisms of any observed effects. Although having a negligible effect on ventricular contractility, the PAR2 activating peptide SLIGRL produced an endothelium-dependent coronary vasodilatation (ED₅₀=3.5 nmol). Following I/R injury, the response to SLIGRL was selectively preserved, whereas the dilator response to acetylcholine was converted to constriction. Trypsin also produced a vasodilator dose-response curve that was biphasic in nature (ED_50-1=0.36 U, ED_50-2=38.71 U). Desensitization of PAR2 receptors indicated that the high potency phase was mediated by PAR2. Removal of the endothelium but not treatment with L-NAME (300 µmol/L), indomethacin (5 µmol/L), or oxyhemoglobin (10 µmol/L) inhibited the response to SLIGRL and trypsin. Treatment with the K⁺-channel blockers TEA (10 mmol/L), charybdotoxin (20 nmol/L)/apamin (100 nmol/L), or elevated potassium (20 mmol/L) significantly suppressed responses. Similarly, inhibition of lipoxygenase with nordihydroguaiaretic acid (1 µmol/L), eicosatetraynoic acid (1 µmol/L), or baicalein (10 µmol/L), desensitization of C-fibers using capsaicin (1 µmol/L, 20 minutes), or blockade of vanilloid (VR1) receptors using capsazepine (3 µmol/L) inhibited the responses. This study shows, for the first time, that PAR2 activation causes endothelium-dependent coronary vasodilation that is preserved after I/R injury and is not mediated by NO or prostanoids, but involves the release of an endothelium-derived hyperpolarizing factor (EDHF), possibly a lipoxygenase-derived eicosanoid, and activation of VR1 receptors on sensory C-fibers.

Key Words: protease-activated receptors • nitric oxide • prostanoid • endothelium-derived hyperpolarizing factor • ischemia/reperfusion injury

This article has been cited by other articles:

				J. L. Strande, M. E. Widlansky, N. E. Tsopanoglou, J. Su, J. Wang, A. Hsu, K. V. Routhu, and J. E. Baker Parstatin: a cryptic peptide involved in cardioprotection after ischaemia and reperfusion injury Cardiovasc Res, July 15, 2009; 83(2): 325 - 334. [Abstract] [Full Text] [PDF]

				M. Wald Exogenous Proteases Confer a Significant Chemopreventive Effect in Experimental Tumor Models Integr Cancer Ther, December 1, 2008; 7(4): 295 - 310. [Abstract] [PDF]

				T. Miyahara, K. Hamanaka, D. S. Weber, M. Anghelescu, J. R. Frost, J. A. King, and J. C. Parker Cytosolic phospholipase A2 and arachidonic acid metabolites modulate ventilator-induced permeability increases in isolated mouse lungs J Appl Physiol, February 1, 2008; 104(2): 354 - 362. [Abstract] [Full Text] [PDF]

				R. Jiang, A. Zatta, H. Kin, N. Wang, J. G. Reeves, J. Mykytenko, J. Deneve, Z.-Q. Zhao, R. A. Guyton, and J. Vinten-Johansen PAR-2 activation at the time of reperfusion salvages myocardium via an ERK1/2 pathway in in vivo rat hearts Am J Physiol Heart Circ Physiol, November 1, 2007; 293(5): H2845 - H2852. [Abstract] [Full Text] [PDF]

				A. Sexton, M. McDonald, C. Cayla, C. Thiemermann, and A. Ahluwalia 12-Lipoxygenase-derived eicosanoids protect against myocardial ischemia/reperfusion injury via activation of neuronal TRPV1 FASEB J, September 1, 2007; 21(11): 2695 - 2703. [Abstract] [Full Text] [PDF]

				L. Moussa, J. Apostolopoulos, P. Davenport, J. Tchongue, and P. G. Tipping Protease-Activated Receptor-2 Augments Experimental Crescentic Glomerulonephritis Am. J. Pathol., September 1, 2007; 171(3): 800 - 808. [Abstract] [Full Text] [PDF]

				J. You, E. M. Golding, and R. M. Bryan Jr. Arachidonic acid metabolites, hydrogen peroxide, and EDHF in cerebral arteries Am J Physiol Heart Circ Physiol, September 1, 2005; 289(3): H1077 - H1083. [Abstract] [Full Text] [PDF]

				M. Steinhoff, J. Buddenkotte, V. Shpacovitch, A. Rattenholl, C. Moormann, N. Vergnolle, T. A. Luger, and M. D. Hollenberg Proteinase-Activated Receptors: Transducers of Proteinase-Mediated Signaling in Inflammation and Immune Response Endocr. Rev., February 1, 2005; 26(1): 1 - 43. [Abstract] [Full Text] [PDF]

				S. F. Steinberg The Cardiovascular Actions of Protease-Activated Receptors Mol. Pharmacol., January 1, 2005; 67(1): 2 - 11. [Abstract] [Full Text] [PDF]

				X. Wang, M. D. Hollenberg, and R. Loutzenhiser Redundant signaling mechanisms contribute to the vasodilatory response of the afferent arteriole to proteinase-activated receptor-2 Am J Physiol Renal Physiol, January 1, 2005; 288(1): F65 - F75. [Abstract] [Full Text] [PDF]

				A. K Chan, N. Vergnolle, M. D Hollenberg, and P.-Y. von der Weid Proteinase-activated receptor 2 activation modulates guinea-pig mesenteric lymphatic vessel pacemaker potential and contractile activity J. Physiol., October 15, 2004; 560(2): 563 - 576. [Abstract] [Full Text] [PDF]

				A. Hobbs, P. Foster, C. Prescott, R. Scotland, and A. Ahluwalia Natriuretic Peptide Receptor-C Regulates Coronary Blood Flow and Prevents Myocardial Ischemia/Reperfusion Injury: Novel Cardioprotective Role for Endothelium-Derived C-Type Natriuretic Peptide Circulation, September 7, 2004; 110(10): 1231 - 1235. [Abstract] [Full Text] [PDF]

				Y. Dai, T. Moriyama, T. Higashi, K. Togashi, K. Kobayashi, H. Yamanaka, M. Tominaga, and K. Noguchi Proteinase-Activated Receptor 2-Mediated Potentiation of Transient Receptor Potential Vanilloid Subfamily 1 Activity Reveals a Mechanism for Proteinase-Induced Inflammatory Pain J. Neurosci., May 5, 2004; 24(18): 4293 - 4299. [Abstract] [Full Text] [PDF]

				C Napoli, F de Nigris, J L Wallace, M D Hollenberg, G Tajana, G De Rosa, V Sica, and G Cirino Evidence that protease activated receptor 2 expression is enhanced in human coronary atherosclerotic lesions J. Clin. Pathol., May 1, 2004; 57(5): 513 - 516. [Abstract] [Full Text] [PDF]

				A. Kawabata, S. Kubo, Y. Nakaya, T. Ishiki, R. Kuroda, F. Sekiguchi, N. Kawao, and H. Nishikawa Distinct roles for protease-activated receptors 1 and 2 in vasomotor modulation in rat superior mesenteric artery Cardiovasc Res, March 1, 2004; 61(4): 683 - 692. [Abstract] [Full Text] [PDF]

				W. B. Veldhuis, M. van der Stelt, M. W. Wadman, G. van Zadelhoff, M. Maccarrone, F. Fezza, G. A. Veldink, J. F. G. Vliegenthart, P. R. Bar, K. Nicolay, et al. Neuroprotection by the Endogenous Cannabinoid Anandamide and Arvanil against In Vivo Excitotoxicity in the Rat: Role of Vanilloid Receptors and Lipoxygenases J. Neurosci., May 15, 2003; 23(10): 4127 - 4133. [Abstract] [Full Text] [PDF]

				M. R. D'Andrea, M. R. Saban, N.-B. Nguyen, P. Andrade-Gordon, and R. Saban Expression of Protease-Activated Receptor-1, -2, -3, and -4 in Control and Experimentally Inflamed Mouse Bladder Am. J. Pathol., March 1, 2003; 162(3): 907 - 923. [Abstract] [Full Text] [PDF]

				J. Robin, R. Kharbanda, P. Mclean, R. Campbell, and P. Vallance Protease-Activated Receptor 2-Mediated Vasodilatation in Humans In Vivo: Role of Nitric Oxide and Prostanoids Circulation, February 25, 2003; 107(7): 954 - 959. [Abstract] [Full Text] [PDF]

				R. C. Landis Aprotinin: Antithrombotic and Vasoactive Mechanisms of Action Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2002; 6(4): 307 - 312. [Abstract] [PDF]

				A. F. Milia, M. B. Salis, T. Stacca, A. Pinna, P. Madeddu, M. Trevisani, P. Geppetti, and C. Emanueli Protease-Activated Receptor-2 Stimulates Angiogenesis and Accelerates Hemodynamic Recovery in a Mouse Model of Hindlimb Ischemia Circ. Res., August 23, 2002; 91(4): 346 - 352. [Abstract] [Full Text] [PDF]

				A. Maree and D. Fitzgerald PAR2 Is Partout and Now in the Heart Circ. Res., March 8, 2002; 90(4): 366 - 368. [Full Text] [PDF]